Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-N53 topical ascending-dose safety study in systemic sclerosis digital ulcers
2024-511861-12-00Phase 2Authorised
- Sponsor
- Topadur Pharma AG
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of TOP-N53 in systemic sclerosis-related digital ulcer (DU) and systemic sclerosis (SSc) (4 arms), sponsored by Topadur Pharma AG. Primary endpoints: Local treatment-emergent adverse events and Investigator-solicited digital ulcer pain. Planned start Feb 2025; status: authorised.
02
Drugs
TOP-N53
03
Conditions
systemic sclerosis-related digital ulcer (DU)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2024-511861-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511861-12-00.